This HTML5 document contains 26 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n5http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n4http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C47757
rdf:type
owl:Class
rdfs:label
Timolol
rdfs:subClassOf
nci:C29576
nci:A5
nci:C29501
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance
nci:P108
Timolol
nci:P207
C0040233
nci:P210
91524-16-2
nci:P319
817W3C6175
nci:P322
FDA
nci:P350
2C13H24N4O3S.H2O
nci:P366
Timolol
nci:P368
CHEBI:60787
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Blocadren</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Betimol</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>TIMOLOL</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>817W3C6175</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Timolol</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>30216</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Timolol</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, hemihydrate, (S)-</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A propanolamine derivative and a non-selective beta-adrenergic antagonist with antihypertensive property. Timolol competitively binds to beta-1-adrenergic receptors in the heart and vascular smooth muscle and beta-2-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in beta-adrenergic stimulation. Beta-1-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta-2-blockade results in an increase in peripheral vascular resistance. The ultimate results include vasodilation, and negative chronotropic and inotropic cardiac effects. In addition, timolol reduces intra-ocular pressure possibly by decreasing aqueous humor production by reduction of blood flow to the ciliary processes and cAMP synthesis.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C47757
owl:sameAs
n4:N0000006504 n5:817W3C6175
n7:hasConcept
n8:M0021546